Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 19:2022:5763810.
doi: 10.1155/2022/5763810. eCollection 2022.

Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study

Melih Simsek  1 , Altay Aliyev  1 , Tuba Baydas  2 , Mehmet Besiroglu  1 , Tarik Demir  1 , Abdallah Tm Shbair  1 , Mesut Seker  1 , H Mehmet Turk  1
Affiliations

Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study

Melih Simsek et al. Breast J. .

Abstract

The prognosis of breast cancer patients with brain metastasis is poor. It was aimed to define the clinicopathological features of breast cancer patients with brain metastases and to determine the risk factors and survival outcomes associated with brain metastasis. This is a single-center, retrospective, cross-sectional study. A total number of 127 patients diagnosed with breast cancer and who developed brain metastasis between January 2011 and March 2021 were retrospectively analyzed. The survival and clinicopathological data of these patients according to 4 biological subtypes were evaluated (luminal A, luminal B, HER-2 overexpressing, and triple-negative). The median overall survival for all patients was 45.6 months. The median time from the diagnosis of breast cancer to the occurrence of brain metastasis was 29.7 months, and the median survival time after brain metastasis was 7.2 months. The time from the diagnosis of breast cancer to brain metastasis development was significantly shorter in HER-2 overexpressing and triple-negative subtypes than in luminal A and B subtypes. The median time from breast cancer diagnosis to brain metastasis was 33.5 months in luminal A, 40.6 months in luminal B, 16.8 months in HER-2 overexpressing, and 22.8 months in the triple-negative groups (p=0.003). We found the worst median survival after brain metastasis in the triple-negative group with 3.5 months. Early and close surveillance of high-risk patients may help early diagnosis of brain metastasis and may provide to perform effective treatments leading to longer overall survival times for this patient population.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Survival analysis according to breast cancer subtypes.
See this image and copyright information in PMC

References

    1. Soni A., Ren Z., Hameed O., et al. Breast cancer subtypes predispose the site of distant metastases. American Journal of Clinical Pathology . 2015;143(4):471–478. doi: 10.1309/ajcpyo5fsv3upexs. - DOI - PubMed
    1. Arslan U. Y., Oksuzoglu B., Aksoy S., et al. Breast cancer subtypes and outcomes of central nervous system metastases. The Breast . 2011;20(6):562–567. doi: 10.1016/j.breast.2011.07.017. - DOI - PubMed
    1. Fidler I. J. The biology of brain metastasis: challenges for therapy. The Cancer Journal . 2015;21(4):284–293. doi: 10.1097/ppo.0000000000000126. - DOI - PubMed
    1. Barnholtz-Sloan J. S., Sloan A. E., Davis F. G., Vigneau F. D., Lai P., Sawaya R. E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. Journal of Clinical Oncology . 2004;22(14):2865–2872. doi: 10.1200/jco.2004.12.149. - DOI - PubMed
    1. Mills M. N., Figura N. B., Arrington J. A., et al. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Research and Treatment . 2020;180(2):279–300. doi: 10.1007/s10549-020-05552-2. - DOI - PubMed